S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
NASDAQ:IMV

IMV (IMV) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$0.49
$0.91
52-Week Range
N/A
Volume
44,800 shs
Average Volume
233,607 shs
Market Capitalization
$9.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
IMV stock logo

About IMV Stock (NASDAQ:IMV)

IMV, Inc. is a clinical-stage biopharmaceutical company, which engage in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. Its immune-educating technology includes DPX which is designed to inform a specific, coordinated, and persistent anti-tumor immune response. The company was founded on May 18, 2007 and is headquartered in Dartmouth, Canada.

IMV Stock News Headlines

Healthcare Takes A Big Step Forward With The Help Of AI
The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.
Philippines sales up in February 2024
Healthcare Takes A Big Step Forward With The Help Of AI
The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.
Q4 2023 Horizon Technology Finance Corp Earnings Call
Don't Fall For These 12 Fried Chicken Myths
See More Headlines
Receive IMV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IMV and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/11/2021
Today
4/17/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:IMV
Fax
N/A
Employees
97
Year Founded
N/A

Profitability

Net Income
$-37,990,000.00
Net Margins
-11,547.42%
Pretax Margin
-11,547.42%
Return on Equity
-12,695.41%

Debt

Sales & Book Value

Annual Sales
$330,000.00
Book Value
($0.69) per share

Miscellaneous

Free Float
11,673,000
Market Cap
$9.63 million
Optionable
Optionable
Beta
0.95
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Andrew Hall
    Chief Executive Office & Director
  • Jennifer Schmitke
    Chief Operating Officer
  • Brittany Davison
    Chief Accounting Officer, Director & SVP-finance
  • Jeremy R. Graff
    Chief Scientific Officer
  • Stéphane Fiset
    Vice President-Clinical Research

IMV Stock Analysis - Frequently Asked Questions

Should I buy or sell IMV stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IMV in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" IMV shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IMV, but not buy additional shares or sell existing shares.
View IMV analyst ratings
or view top-rated stocks.

How were IMV's earnings last quarter?

IMV Inc. (NASDAQ:IMV) posted its quarterly earnings results on Thursday, November, 11th. The company reported ($1.30) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($1.30). The business had revenue of $0.04 million for the quarter. IMV had a negative net margin of 11,547.42% and a negative trailing twelve-month return on equity of 12,695.41%. During the same period in the prior year, the business posted ($1.00) EPS.

When did IMV's stock split?

IMV's stock reverse split before market open on Tuesday, December 13th 2022. The 1-10 reverse split was announced on Tuesday, December 13th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, December 13th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

This page (NASDAQ:IMV) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners